Skip to main content

Table 3 Assessment of efficacy and safety based on laboratory data (the long-term continual use group)

From: A laboratory data-based evaluation of the efficacy and safety of generic pravastatin sodium for long-term use

 

Short-term treatment

Long-term treatment

 

Plasma parameter

Mean ± S.D.

N

Mean ± S.D.

N

p-value

TC

195

±

25.0

407

196

±

28.5

417

0.42

TG

129

±

76.8

405

123

±

65.5

449

0.16

HDL-C

60.8

±

15.6

388

61.9

±

16.6

437

0.32

LDL-C

109

±

20.1

239

112

±

24.0

246

0.06

AST

24.2

±

12.2

419

23.2

±

9.29

473

0.19

ALT

23.1

±

21.6

418

20.4

±

11.3

473

0.02

CPK

112

±

86.5

358

108

±

67.9

395

0.51

γ-GTP

35.3

±

52.4

324

33.0

±

35.5

385

0.50

ALP

236

±

72.1

266

245

±

81.8

286

0.18

T-Bil

0.66

±

0.25

242

0.67

±

0.27

303

0.91

LDH

198

±

37.4

372

196

±

39.1

417

0.48

BUN

17.0

±

8.78

384

17.6

±

8.39

461

0.27

Scr

0.87

±

0.55

413

0.91

±

0.74

478

0.40

HbA1c

6.26

±

0.83

308

6.24

±

0.88

341

0.87

  1. Total plasma cholesterol, TC; triglyceride, TG; high-density lipoprotein cholesterol, HDL-C; low-density lipoprotein cholesterol, LDL-C; aspartate aminotransferase, AST; alanine aminotransferase, ALT; creatine phosphokinase, CPK; gamma-glutamyl transferase, γ-GTP; alkaline phosphatase, ALP; lactate dehydrogenase, LDH; total bilirubin, T-Bil; blood urea nitrogen, BUN; serum creatinine, Scr; hemoglobin A1c, HbA1c; standard deviation, S.D
Back to article page

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us